Outcomes of Radium-223 and Stereotactic Ablative Radiotherapy Versus Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancers: The RAVENS Phase II Randomized Trial

Overview of attention for article published in Journal of Clinical Oncology, May 2025

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (93rd percentile)

Mentioned by

news: 4 news outlets
blogs: 2 blogs
twitter: 31 X users

guideline: 1 clinical guideline source
bluesky: 1 Bluesky user

Readers on

mendeley: 23 Mendeley

So far, Altmetric has seen 2 Bluesky posts from 1 Bluesky users, with an upper bound of 2 followers.

Radium-223 addition to stereotactic ablative radiotherapy for bone metastatic prostate cancer showed no benefit in delaying disease progression. by Wang JH, Sherry AD (...) Kiess AP et 31 al. in J Clin Oncol #MedSky 👉 get more here 📖 read the article…

Combining Radium-223 with SABR in bone metastatic prostate cancer fails to improve progression-free survival. by Wang JH, Sherry AD (...) Kiess AP et 31 al. in J Clin Oncol #MedSky 👉 get more here 📖 read the article: https://ascopubs.org/doi/10.1200/…

This page shows the most recent Bluesky posts that mention this research output. Click here to find out how to access more activity.